|
業務類別
|
Biotechnology |
|
業務概覽
|
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily,selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. |
| 公司地址
| 9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 369-7100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.litestrategy.com |
| 員工數量
| 4 |
| Mr. Justin J. File |
Director, Chief Executive officer, Chief Financial Officer and Corporate Secretary |
美元 541.67K |
18/11/2025 |
|
|
| Mr. Justin J. File |
Director, Chief Executive officer, Chief Financial Officer and Corporate Secretary |
18/11/2025 |
| Mr. Frederick W. Driscoll |
Chairman of the board |
30/12/2025 |
| Mr. Joshua Riezman |
Director |
06/08/2025 |
| Mr. Charlie Lee |
Director |
22/07/2025 |
| Dr. Nicholas R. Glover, PhD |
Independent Director |
30/12/2025 |
| Mr. Charles B. Lee |
Director |
30/12/2025 |
|
|
|
|
